Funding for this research was provided by:
Shanghai Association for Science and Technology (E4-6100-21-201034)
Received: 21 May 2023
Accepted: 1 July 2023
First Online: 27 July 2023
: The trial was approved by the Ethics Committee of Shanghai Medical College (Approval Number: 2022-E4-6100) and registered with the China Clinical Trial Registration Center (Registration Number: ChiCTR220066184) in December 2022. All participants will provide written informed consent following the Helsinki Declaration before participating. The subjects voluntarily participate in the study, fully informing them of the purpose and requirements of the study, ensuring that they have the right to choose to participate or withdraw freely and that relevant interests are not harmed. Inform the subjects of the confidentiality principles of the study and their rights during the treatment process, and sign an informed consent form. The Ethics Committee of Shanghai Medical College approves them.
: This manuscript does not contain individual personal data from patients. In addition to the current information: “Not applicable—the participant information materials and informed consent form are available from the corresponding author on request.”
: The authors declare that they have no competing interest.